Adjuvant treatment of high grade gliomas

Size: px
Start display at page:

Download "Adjuvant treatment of high grade gliomas"

Transcription

1 17 (Supplement 10): x186 x190, 2006 doi: /annonc/mdl258 Adjuvant treatment of high grade gliomas M. J. van den Bent Department of Neuro-Oncology, Erasmus University Hospital Rotterdam/Rotterdam Cancer Center, Rotterdam, The Netherlands introduction Gliomas are the most frequent primary brain tumours in adults. They are usually classified and graded according to the World Health Organisation (WHO) criteria [1]. Most gliomas are considered diffuse glioma, which refers to their infiltrative growth pattern. Histologically, they are classified into astrocytoma, oligodendroglioma, oligoastrocytoma (which at the genetic level are either oligodendroglioma or astrocytoma) and ependymoma (which are rather rare). Low-grade tumours have a median of 5 15 years, but median is between 2 and 4 years for anaplastic astrocytoma and only months for the most malignant primary brain tumour, the glioblastoma multiforme (GBM). No matter how extensive a glioma is resected, due to the infiltrative nature of the tumour, resection will never be radical from the surgical point of view. Moreover, it has been shown that the surgeon s estimate of the extent of resection made during surgery is unreliable, and magnetic resonance (MR) spectroscopy or positron emission tomography (PET) imaging may reveal tumour in areas that are considered normal on standard T1 and T2 weighted MR imaging [2 4]. In addition, due to the localization of the tumour in eloquent areas often only a limited resection or just a biopsy is possible. Thus, in contrast to other diseases in oncology where adjuvant treatment is given to eradicate microscopic disease, in glioma, post-surgical adjuvant treatment is indicated to treat macroscopic disease. The goal of the adjuvant treatment is not to cure the patient, as in virtually all patients the tumour will eventually recur, but to prolong overall in a clinically good condition. Several recent trials both in high-grade and in low-grade tumours have shown increased progression-free without effecting overall after more intense treatment at first diagnosis [e.g. early radiotherapy, adjuvant procarbazinelomustine-vincristine (PCV) chemotherapy] [5 7]. Postponing progression may help to keep the neurological condition of a brain tumour patient stable, but whether indeed in general quality of life is improved by aggressive initial treatment in newly diagnosed patients is unknown. Salvage chemotherapy at the time of progression allows the determination of responsiveness of the tumour, which is usually not possible in patients treated with adjuvant chemotherapy after radiotherapy. Thus, in the case of adjuvant chemotherapy, patients with chemotherapy-resistant tumours will receive the full series of chemotherapy without any benefit. Randomised controlled clinical trials conducted from 1970 to the 1990s have demonstrated that radiotherapy (RT) to a dosage of Gray (Gy) improves the of high-grade glioma patients (Table 1) [8 10]. Furthermore, radiotherapy with or without chemotherapy was found to be more effective than chemotherapy alone [8, 11, 12]. Attempts to increase further with RT-dose intensification have not been successful [13 15]. This implies that for further improvement of treatment outcome other treatment modalities are required [13 15]. chemotherapy Virtually all trials on classical adjuvant chemotherapy, administered sequentially with radiotherapy and usually with nitrosourea (carmustine, lomustine) failed to improve overall outcome [11, 16]. It took a large, individual patient database meta-analysis comprising over 3000 patients to show that this kind of adjuvant chemotherapy may indeed result in a very modest 5% increase in 2-year (from 15% to 20%; Table 1) [17]. In recent years the role of chemotherapy in glioma has been met with renewed interest mainly due to two developments: the improved outcome of GBM treated with concurrent radiotherapy and daily temozolomide (TMZ) followed by six cycles of adjuvant temozolomide; and the recognition of the sensitivity to chemotherapy of 1p/19q loss oligodendrogliomas. temozolomide for patients with newly diagnosed glioblastoma multiforme After the phase II trial by Stupp et al. demonstrated the safety of daily low-dose TMZ (75 mg/m 2 daily 7 day/week) combined with radiotherapy for up to 7 weeks, followed by six cycles of adjuvant TMZ (5 days q28 days) the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCI-C) Clinical Trials Group compared this combined chemoradiation regimen to standard radiotherapy alone in a large prospective randomised phase III trial in 573 patients [18, 19]. This study unequivocally demonstrated that the combination of TMZ and radiotherapy followed by up to six cycles of adjuvant TMZ improves. Patients randomised to the combined modality treatment received daily 75 mg/m 2 for the entire 6-week period of radiotherapy (also at the weekends), and after the end of radiotherapy six cycles of adjuvant treatment given at mg/m 2 on day 1 5 every 4 weeks (Figure 1). Patients received Pneumocystis carinii pneumonia prophylaxis during the concomitant phase with oral cotrimoxazol or pentidine ª 2006 European Society for Medical Oncology

2 inhalations, and during the adjuvant phase anti-emetic treatment with 5-hydroxytryptamine-3 (5HT 3 ) antagonists. With this combined modality treatment the 2-year increased from 10% to 27% (Table 1). Patients with a modest performance status showed limited if any benefit from the addition of chemotherapy; for patients having undergone a biopsy only, the benefit was statistically not significant (which may have been due to the limited number of patients in this group). Overall, the combined treatment was well tolerated; the main reason for early discontinuation was disease progression. Quality of life analysis using the EORTC C30 and the brain cancer specific module BCM20 showed that the combined modality treatment did not have significant adverse effects on the quality of life [20]. Table 1. Median, 1- and 2-year after various postoperative adjuvant treatment in high grade glioma Reference Treatment Median (months) 1-year 2-year Walker [8] Supportive care 3 3% 0 BCNU 4 12% 0 RT 8 24% 1% RT + BCNU 8 32% 5% Glioma Metaanalysis Trialists Group [17] EORTC [19] RT 40% 15% RT + CTX 46% 20% RT 12 51% 10% RT + temozolomide 15 61% 27% The outcome of EORTC study is given in bold. RT, radiotherapy; CTX, chemotherapy; SRS, stereotactic radiosurgery; BCNU, carmustine. O 6 -methylguanine DNA methyltransferase Both nitrosoureas and TMZ act as DNA alkylating and methylating agents. Alkylation of the O 6 -position of guanine is one among many DNA adducts formed, but it is of major importance for the induction of mutations and for the cytotoxic action of these drugs. During subsequent DNA replication, the methylated guanine pairs with thymidine instead of cytidine, which incites futile mismatch repair and eventually may induce apoptosis. Cells have the capacity of restoring guanine through the DNA excision repair enzyme O 6 -methylguanine-dna methyltransferase (MGMT), also known as O 6 -alkyl-guaninealkyltransferase (AGAT), during which process the enzyme is inactivated (see review by Gerson et al.) [21]. High endogenous MGMT activity in cancer cells blunts the treatment effect of alkylating agent chemotherapies creating a resistant phenotype, whereas the absence of MGMT or the inability to produce MGMT makes the cell vulnerable to alkylating agents. Indeed, silencing of the MGMT gene by promoter methylation that impairs expression of the DNA repair enzyme has been associated with prolonged in glioma patients treated with nitrosourea s or with TMZ [22 24]. The clinical relevance of the mechanistic implication of the DNA repair enzyme alkyltransferase in alkylating chemotherapy was tested in the randomised EORTC/NCIC trial on GBM. Samples from 206 patients could be analysed for the status of the MGMT gene promoter using methylation-specific polymerase chain reaction (PCR) [25]. In 45% of the tumour samples the MGMT gene promoter was methylated and thus the gene was silenced. Overall, patients with a silenced MGMT gene had a longer. Breakdown of the data by treatment strongly suggests that the MGMT methylation status is a predictive marker for benefit from TMZ chemotherapy. For patients in the TMZ/RT arm the 2-year rate was 46% when their tumour presented a methylated MGMT status in contrast to only 14% in patients with an unmethylated MGMT gene promoter (Table 2). Thus, in this molecularly defined subgroup TMZ appears even more effective increasing the median by 9 months to 21.7, while patients with an unmethylated MGMT gene promoter had little if any TMZ-derived benefit with a median of 12.7 months. A confirmation of these findings and validation of assays is required before this test can be used in daily clinical practice. Figure 1. Treatment schedule for concomitant/adjuvant temozolomide and radiotherapy. treatment of elderly and of poor prognosis GBM patients Several investigators have tried to shorten the treatment period for poor prognosis patients (usually defined as patients in poor clinical condition, or with an age over years) by giving Table 2. Median and 2-year in EORTC study in relation to the methylation status of the MGMT promotor [25] Treatment Median (months) 2-year (%) Radiotherapy a Radiotherapy plus temozolomide Radiotherapy a Radiotherapy plus temozolomide Unmethylated MGMT promotor 11.8 months 12.7 months <2% 13.8% Methylated MGMT promotor 15.3 months 21.7 months 22.7% 46% a 72% of the patients in the radiotherapy-arm received alkylating chemotherapy at recurrence. Volume 17 Supplement 10 September 2006 doi: /annonc/mdl258 x187

3 hypofractionated radiotherapy. A Canadian randomized trial in elderly patients recently showed that indeed there is no differences between standard 60 Gy RT and a shortened course of RT (40 Gy in 15 fractions) in patients over 70 years of age [26]. The advantage of this shortened schedule in elderly patients is of course the much shorter treatment duration. Many institutions have a conservative approach to elderly patients and often only offer best palliative care without radiotherapy. A French study in anaplastic glioma patients over 70 years of age with a Karnofski performance status (KPS) of 70 or higher compared 50 Gy in 28 fractions to best palliative care [27]. Radiotherapy increased progression-free from 7 to 14 weeks and median from 18 to 29 weeks. Thus, although radiotherapy clearly increases, the increase in after radiotherapy is modest and even after radiotherapy the outlook is poor. One may consider treating elderly patients only if they are in a good condition, in which case a short course of radiotherapy may be appropriate. Once it became clear that adding daily TMZ to radiotherapy improved outcome in GBM patients (even in the age cohort years), the obvious question was whether patients over 70 years of age and patients treated with a short radiotherapy schedule also benefit from the addition of TMZ. One may assume that if a benefit is present this will be less significant, but this needs further study. Because of reports of high response and disease stabilisation rates with TMZ chemotherapy in previously untreated GBM patients [28], chemotherapy instead of radiotherapy has been evaluated in a limited number of elderly patients in uncontrolled trials. One prospective study on 32 patients reported a median of 6.4 months [29]. A second (nonrandomized) trial observed a outcome after treatment with TMZ (n = 32) that was at least as good as historical controls with similar prognostic characteristics treated with radiotherapy in the same time period within the same institution [30]. The treatment outcome of these two studies appears similar compared with the results of radiotherapy only in elderly or poor prognosis GBM patients [26, 31]. In both studies toxicity was modest, although in one study dose delays and dose reductions were needed in 38% and 13% of patients. This underlines the need for a more cautious approach to chemotherapy in elderly patients. Several new randomized studies are exploring the role of concomitant TMZ with radiotherapy (either short course or the full 60 Gy schedule) or treatment with TMZ only. Of course, one goal here is to avoid too intensive treatments of long duration in a frail population with a limited prognosis. adjuvant chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma Oligodendroglioma and, to a lesser extent, oligoastrocytoma are responsive to chemotherapy. Two-thirds of patients with recurrent tumours were shown to respond to PCV chemotherapy or to TMZ [32 34]. Further molecular studies showed that in particular patients with oligodendrogliomas with loss of heterozygosity on both the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) are very sensitive to PCV and to TMZ chemotherapy, although the underlying mechanism is still unclear [34 36]. The recent finding of a high percentage of these tumours with a methylated MGMT status (>80%) may at least in part explain this sensitivity [37]. Both the RTOG and the EORTC investigated the addition of PCV chemotherapy to radiotherapy in newly diagnosed anaplastic oligodendroglioma [6, 7]. The RTOG study used a neo-adjuvant dose-intensified PCV schedule, whereas the EORTC study used a classical adjuvant design with standard PCV. In both studies the control arm received radiotherapy only, but further treatment at the time of progression was left to the discretion of the treating physician. Most patients received further chemotherapy at the time of progression. Although both studies observed an increase in progression-free in the PCV arm, this did not translate in an increase in overall (Table 3). In contrast to the EORTC study, the RTOG study did not observe an increase in progressionfree in the non-1p/19q deleted tumours. Patients with 1p/19q loss had a clearly better outcome (median over 6 7 years compared with 2 3 years in patients without 1p/19q loss), but this improved outcome was regardless of treatment (data not shown). Both studies show, that in this relatively chemosensitive tumour the timing of chemotherapy is not relevant (at first diagnosis or at recurrence), as long as it is given. Despite the absence of a formal trial many clinicians today propose upfront TMZ as first treatment in 1p/19q loss oligodendroglioma. This is an unproven approach, in part based on the assumption that RT is likely to induce delayed cognitive deficits. This assumption is questionable if modern RT techniques are used with dose fractions of less than 2 Gy [38]. Eventually, this may be more a matter of side-effects and one should realize that especially for limited size lesions RT offers an effective treatment of short duration (6 weeks instead of months of chemotherapy) with prolonged tumour control. anaplastic astrocytoma Past trials in general showed similar outcome to classical adjuvant chemotherapy of anaplastic astrocytoma compared with GBM [16]. With the improved outcome after treatment with adjuvant and concomitant TMZ in GBM (see the section on GBM), the question is whether this treatment should also be given to anaplastic astrocytoma [19]. In view of the superior outcome of combined modality treatment this seems logical, but it is at present unknown if combined modality treatment may cause an increased delayed neurotoxicity in patients with a longer. Whatever the explanation, the currently Table 3. Median overall and progression-free in EORTC study and RTOG study with adjuvant PCV in anaplastic oligodendroglioma Overall Progression-free RT RT/PCV RT RT/PCV EORTC [7] 30.6 months 40.3 months 13 months 23 months RTOG [6] 4.7 years 4.9 years 1.7 years 2.6 years RT, radiotherapy; RT/PCV, radiotherapy followed by adjuvant PCV chemotherapy. x188 van den Bent Volume 17 Supplement 10 September 2006

4 available data fail to provide any evidence that the increased chemosensitivity of recurrent anaplastic astrocytoma compared with GBM is reflected in a higher response rate to neoadjuvant chemotherapy [39]. Reviews of old RTOG/ECOG studies suggested a decreased in more aggressively treated anaplastic astrocytoma patients [40]. These data were, however, obtained from historical comparisons over trials, so the conclusions should be viewed with caution. It probably cannot be taken for granted that approaches showing a superior outcome in GBM will also provide a superior outcome in anaplastic astrocytoma. conclusions Concurrent chemo-irradiation with TMZ is now considered standard of care for adult GBM patients. It is yet unclear if these results can also be extrapolated to other anaplastic glioma. Adjuvant or neoadjuvant PCV chemotherapy does not improve overall in anaplastic oligodendroglioma/ oligoastrocytoma, regardless of genotype, but may prolong progression-free. references 1. World Health Classification of tumours. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for the Research on Cancer Albert FK, Forstin M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumour and its influence on regrowth and prognosis. Neurosurgery 1994; 34: Pirzkall A, Li X, Oh J et al. 3D MRSI for resected high-grade gliomas before RT: tumour extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 2004; 59: Grosu AL, Weber WA, Riedel E et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: van den Bent MJ, Afra D, De Witte O et al. Long term results of EORTC study 22845: a randomized trial on the efficacy of early versus delayed radiation therapy of low-grade astrocytoma and oligodendroglioma in the adult. Lancet (in press). 6. Cairncross JG, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): an intergroup trial by the RTOG, NCCTG, SWOG, NCI CTG and ECOG. J Clin Oncol 2006; 24: van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant PCV improves progression free but not overall in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol 2006; 24: Walker MD, Alexander E, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49: Kristiansen K, Hagen S, Kolleveld T et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleiomyycin on time. Cancer 1981; 47: Andersen AP. Postoperative irradiation of glioblastomas. Acta Radiol Oncol 1978; 17: Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: Sandberg-Wollheim M, Malmström P, Strömblad LG et al. A randomized study of chemotherapy with procarbazine, vincristine and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68: Selker RG, Shapiro WR, Burger P et al. The brain tumour cooperative group NIH trial 87/01± a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002; 51: Laperriere NJ, Leung PKM, McKenzie S et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiation Oncol Biol Phys 1998; 41: Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group protocol. Int J Radiation Oncol Biol Phys 2004; 60: Thomas D, Brada M, Stenning S. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial. J Clin Oncol 2001; 19: Glioma Meta-Analysis Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: Stupp R, Dietrich P-Y, Osterman-Kraljevic S et al. Promising for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: Taphoorn MJB, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 2005; 6: Gerson SL: MGMT: its role in cancer aetiology and cancer therapeutics. Nature Rev 2004: 4: Jaeckle KA, Eyre HJ, Townsend JJ et al. Correlation of tumour O6 methylguanine-dna methyltransferase levels with of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a southwest oncology group study. J Clin Oncol 1999; 16: Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: Hegi ME, Diserens A-C, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 15: Hegi ME, Diserens A-C, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: Roa W, Brasher PMA, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22: Keime-Guibert F, Chinot O-L, Taillandier L et al. Phase 3 study comparing radiotherapy with supportive care inolder patients with newly diangosed anaplastic astrocytomas (AA) or glioblastoma multiforme (GBM): an ANOCEF group trial. Neuro-Oncology 2005; 7: 349 (Abstr 260). 28. Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and 06-alkylguanine-DNA alkyltransferase and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: Chinot O-L, Barrie M, Frauger E et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in elderly populations. Cancer 2004; 100: Glantz M, Chamberlain M, Liu Q et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003; 97: Chang EL, Yi W, Allen PK et al. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. Int J Radiation Oncol Biol Phys 2003; 56: Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12: Volume 17 Supplement 10 September 2006 doi: /annonc/mdl258 x189

5 33. van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology 1998; 51: van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma: the European Organisation of Research and Treatment of Cancer Brain Tumour Group study J Clin Oncol 2003; 21: Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: van den Bent MJ, Looijenga LHJ, Langenberg K et al. Chromosomal anomalies in oligodendroglial tumours are correlated with clinical features. Cancer 2003; 97: Möllemann M, Wolter M, Felsberg J et al. Frequent promotor hypermethylation and low expression of the MGMT gene in oligodendroglial tumours. Int J Cancer 2004; 113: Klein M, Heimans JJ, Aaronson NK et al. Effect of radiotherapy and other treatment-related fators on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet 2002; 360: Brada M, Ashley S, Dowe A et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 2005; 16: Fischbach AJ, Martz KL, Nelson JS et al. Long-term in treated anapalstic astrocytomas. A report of combined RTOG/ECOG studies. Am J Clin Oncol 1991; 14: x190 van den Bent Volume 17 Supplement 10 September 2006

Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma

Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional

More information

Hypofractionated radiation therapy for glioblastoma

Hypofractionated radiation therapy for glioblastoma Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health

More information

Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study

Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly

More information

Neuro-Oncology. Martin J. van den Bent. Department of Neuro-oncology/Neurology, Erasmus M.C. Cancer Institute, Rotterdam, Netherlands

Neuro-Oncology. Martin J. van den Bent. Department of Neuro-oncology/Neurology, Erasmus M.C. Cancer Institute, Rotterdam, Netherlands Neuro-Oncology Neuro-Oncology 16(12), 1570 1574, 2014 doi:10.1093/neuonc/nou297 Advance Access date 29 October 2014 Practice changing mature results of RTOG study 9802: another positive PCV trial makes

More information

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology

More information

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study J Neurooncol (2012) 108:195 200 DOI 10.1007/s11060-012-0832-5 CLINICAL STUDY Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study Walter Taal Joyce M. W. Segers-van Rijn

More information

Precision medicine for gliomas

Precision medicine for gliomas Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,

More information

PRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study

PRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study NOTE: Consider Clinical Trials as treatment options for eligible patients. Page 1 of 6 RADIOLOGICAL PRESENTATION PRESURGICAL PLANNING TREATMENT Imaging study suggestive of glioma 1 Left hemisphere speech/motor

More information

Low grade glioma: a journey towards a cure

Low grade glioma: a journey towards a cure Editorial Page 1 of 5 Low grade glioma: a journey towards a cure Ali K. Choucair SIU School of Medicine, Springfield, IL, USA Correspondence to: Ali K. Choucair, MD. Professor of Neurology, Director of

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas

More information

Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide

Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine

More information

Predictive and Prognostic Markers in Neuro-Oncology

Predictive and Prognostic Markers in Neuro-Oncology J Neuropathol Exp Neurol Copyright Ó 2007 by the American Association of Neuropathologists, Inc. Vol. 66, No. 12 December 2007 pp. 1074Y1081 REVIEW ARTICLE Predictive and Prognostic Markers in Neuro-Oncology

More information

Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide

Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide 405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD

More information

PROCARBAZINE, lomustine, and vincristine (PCV) is

PROCARBAZINE, lomustine, and vincristine (PCV) is RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION

More information

Chemotherapy in Adults with Gliomas

Chemotherapy in Adults with Gliomas 364 Chemotherapy in Adults with Gliomas Siew-Ju See and Mark R Gilbert Review Article Chemotherapy in Adults with Gliomas Siew-Ju See, 1 MBBS (S pore), MRCP (UK), Mark R Gilbert, 2 MD Abstract Treating

More information

성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)

성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015) 성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating

More information

Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma

Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Temozolomide Concomitant and Adjuvant to Radiotherapy in Elderly Patients With Glioblastoma Correlation With MGMT Promoter Methylation Status Alba A. Brandes, MD 1 ; Enrico Franceschi, MD 1 ; Alicia Tosoni,

More information

CNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.

CNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage

More information

3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors

3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors research article 213 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors Yilmaz Tezcan and Mehmet Koc Department

More information

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014 Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer

More information

Contemporary Management of Glioblastoma

Contemporary Management of Glioblastoma Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I

More information

Chemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402

Chemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402 Chemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402 Gregory Cairncross, Meihua Wang, Edward Shaw, Berndt Scheithauer

More information

Background. Central nervous system (CNS) tumours. High-grade glioma

Background. Central nervous system (CNS) tumours. High-grade glioma 25 4. Central nervous system (CNS) tumours Background Two important considerations underpin the choice of treatment fractionation in neurooncology. First, the results of treatment vary widely and, second,

More information

Prior to 1993, the only data available in the medical

Prior to 1993, the only data available in the medical Neuro-Oncology Prospective clinical trials of intracranial low-grade glioma in adults and children Edward G. Shaw 1 and Jeffrey H. Wisoff Department of Radiation Oncology, Wake Forest University School

More information

Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide

Zurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide University of Zurich Zurich Open Repository and Archive Winterthurerstr. 19 CH-857 Zurich http://www.zora.uzh.ch Year: 29 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine

More information

Radioterapia no Tratamento dos Gliomas de Baixo Grau

Radioterapia no Tratamento dos Gliomas de Baixo Grau Radioterapia no Tratamento dos Gliomas de Baixo Grau Dr. Luis Souhami University Montreal - Canada Low Grade Gliomas Relatively rare Heterogeneous, slow growing tumors WHO Classification Grade I Pilocytic

More information

Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.

Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit

More information

Neuro-Oncology Program

Neuro-Oncology Program Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation

More information

Oncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013

Oncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Oncological Management of Brain Tumours Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Outline General considerations of Primary Brain Tumours: epidemiology, pathology, presentation. Diagnosis

More information

doi: /bjr/

doi: /bjr/ doi: 10.1259/bjr/29022270 Prognostic factors in the consecutive institutional series of glioblastoma multiforme patients who received high-dose particle radiotherapy or conventional radiotherapy Masahide

More information

Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas

Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas ONCOLOGY LETTERS 4: 455-460, 2012 Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas MICHAL SPYCH 1,2, LESZEK GOTTWALD 3, EMILIA JESIEŃ LEWANDOWICZ 1,2, SŁAWOMIR

More information

Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience

Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience *Ehab Abdou and **Mohamed Gaafar *Department of Radiation Oncology, Faculty of Medicine, Al-Azhar University, Cairo,

More information

University of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010

University of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010 University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,

More information

Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study

Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:

More information

UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS

UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN

More information

Cilengitide (Impetreve) for glioblastoma multiforme. February 2012

Cilengitide (Impetreve) for glioblastoma multiforme. February 2012 Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Procarbazine Lomustine and VinCRIStine (PCV) Therapy INDICATIONS FOR USE:

Procarbazine Lomustine and VinCRIStine (PCV) Therapy INDICATIONS FOR USE: Procarbazine Lomustine and VinCRIStine (PCV) Therapy INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Adjuvant treatment of Grade II glioma administered after C71 00379a radiotherapy Palliative treatment

More information

Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy

Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy Elderly Patients with Glioblastoma Multiforme Treated with Concurrent Temozolomide and Standard- versus Abbreviated-Course Radiotherapy Christine N Chang-Halpenny, MD; Jekwon Yeh, MD; Winston W Lien, MD

More information

Chemotherapy in malignant brain tumors

Chemotherapy in malignant brain tumors Chemotherapy in malignant brain tumors Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH 4031 Basel zimmermannf@uhbs.ch Tumor types Neuro-epithelial tumors - Glioblastoma

More information

Changing Paradigms An Update on the Multidisciplinary Management of Malignant Glioma

Changing Paradigms An Update on the Multidisciplinary Management of Malignant Glioma This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Neuro Oncology Changing Paradigms An Update on the Multidisciplinary

More information

Radiation and concomitant chemotherapy for patients with glioblastoma multiforme

Radiation and concomitant chemotherapy for patients with glioblastoma multiforme Chinese Journal of Cancer Review Radiation and concomitant chemotherapy for patients with glioblastoma multiforme Salvador Villà 1, Carme Balañà 2 and Sílvia Comas 1 Abstract Postoperative external beam

More information

Management of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS

Management of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS Management of Glioma: The Basics Glioma Update 3 oger Stupp, MD Department of Oncology & Cancer Center University Hospital Zurich, Switzerland (roger.stupp@usz.ch) Bern, 3. August 3 The clinical challenge

More information

Efficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis

Efficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis Efficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis Igal Kushnir MD 1 * and Tzahala Tzuk-Shina MD 2 1 Oncology Insitute, Tel Aviv Sourasky Medical Center,

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING

More information

Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121

Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.

More information

Antiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /

Antiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. / Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases

More information

Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study

Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study ORIGINAL ARTICLE Treatment and outcomes for glioblastoma in elderly compared with non-elderly patients: a population-based study E.R. Morgan md,* A. Norman md, K. Laing md, and M.D. Seal md ABSTRACT Purpose

More information

Clinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment

Clinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: GLIOBLASTOMA MULTIFORME (CNS) Patient information given at each stage following agreed

More information

An international study under the guidance of the European Organization

An international study under the guidance of the European Organization 2617 COMMENTARY Chemotherapy for Glioblastoma Is Costly Better? Ute Linz, MD, PhD Juelich Research Center, IKP/INB, Juelich, Germany. Address for reprints: Ute Linz, MD, PhD, Forschungszentrum J ulich

More information

Imaging for suspected glioma

Imaging for suspected glioma Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless

More information

Going Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D.

Going Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Going Past the Data for Temozolomide J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Departments of Medicine (JLV), Neurosurgery (JLV) and Pharmacy Practice (LRB)

More information

ORIGINAL PAPERS. The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme

ORIGINAL PAPERS. The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme ORIGINAL PAPERS Adv Clin Exp Med 2015, 24, 2, 279 287 DOI: 10.17219/acem/40456 Copyright by Wroclaw Medical University ISSN 1899 5276 Anna Brzozowska 1, 2, A D, Anna Toruń 3, G, Maria Mazurkiewicz1, 2,

More information

Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment

Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Jennifer Wright Neurosurgery SSC Audit Team Jennifer Wright, Rachel Tresman, Cyril Dubois, Surash Surash,

More information

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma original article MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma Monika E. Hegi, Ph.D., Annie-Claire Diserens, M.Sc., Thierry Gorlia, M.Sc., Marie-France Hamou, Nicolas de Tribolet, M.D.,

More information

Glioblastoma: Current Treatment Approach 8/20/2018

Glioblastoma: Current Treatment Approach 8/20/2018 Glioblastoma: Current Treatment Approach 8/20/2018 Overview What is Glioblastoma? How is it diagnosed How is it treated? Principles of Treatment Surgery, Radiation, Chemotherapy Current Standard of care

More information

UNDERSTANDING MOLECULAR TESTING IN BRAIN TUMORS: HOW CLINICALLY USEFUL IS IT?

UNDERSTANDING MOLECULAR TESTING IN BRAIN TUMORS: HOW CLINICALLY USEFUL IS IT? UNDERSTANDING MOLECULAR TESTING IN BRAIN TUMORS: HOW CLINICALLY USEFUL IS IT? Seema Nagpal, MD Stanford University Stanford, CA Goals: 1. Describe the most commonly used tests in glioma, including MGMT,

More information

Temozolomide in the treatment of recurrent malignant glioma in Chinese patients!"#$%&'()*+,-./0,1234

Temozolomide in the treatment of recurrent malignant glioma in Chinese patients!#$%&'()*+,-./0,1234 Key words: Astrocytoma; Brain neoplasms; Disease-free survival; Glioblastoma; Neoplasm recurrence!!"!"!"#$ DTM Chan WS Poon YL Chan HK Ng Hong Kong Med J 2005;11:452-6 The Chinese University of Hong Kong,

More information

ORE Open Research Exeter

ORE Open Research Exeter ORE Open Research Exeter TITLE Temozolomide for high grade glioma AUTHORS Hart, MG; Garside, R; Rogers, G; et al. JOURNAL Cochrane Database Of Systematic Reviews DEPOSITED IN ORE 22 October 2013 This version

More information

BRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER

BRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER BRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER Kathryn M Field and Mark A Rosenthal Department of Medical Oncology, Royal Melbourne Hospital, Victoria, Australia.

More information

Publisher s version PDF Faculty of Biology and Medicine Publication

Publisher s version PDF Faculty of Biology and Medicine Publication Serveur Académique Lausannois SERVAL serval.unil.ch Publisher s version PDF Faculty of Biology and Medicine Publication Title: MGMT gene silencing and benefit from temozolomide in glioblastoma. Authors:

More information

EORTC (RTOG 0834 Endorsed) Opened: July 22, 2009

EORTC (RTOG 0834 Endorsed) Opened: July 22, 2009 January 2011 0834-1 EORTC 26053 22054 (RTOG 0834 Endorsed) Protocol Status: Opened: July 22, 2009 Title: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic

More information

Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme

Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme Original article Annals of Oncology 16: 1177 1184, 2005 doi:10.1093/annonc/mdi225 Published online 27 April 2005 Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable

More information

Interferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas

Interferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas MOLECULAR AND CLINICAL ONCOLOGY 3: 909-913, 2015 Interferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas HIROSHI KAWAJI, TSUTOMU TOKUYAMA, TOMOHIRO YAMASAKI,

More information

CNAJ12TZRT. Protocol Code. Neuro-Oncology. Tumour Group. Dr. Brian Thiessen. Contact Physician

CNAJ12TZRT. Protocol Code. Neuro-Oncology. Tumour Group. Dr. Brian Thiessen. Contact Physician BC Cancer Protocol Summary for Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Astrocytomas and Oligodendrogliomas with Radiation Protocol Code Tumour Group Contact

More information

Primary Brain Tumors: Characteristics, Practical Diagnostic and Treatment Approaches

Primary Brain Tumors: Characteristics, Practical Diagnostic and Treatment Approaches Primary Brain Tumors: Characteristics, Practical Diagnostic and Treatment Approaches Kraig Moore and Lyndon Kim Abstract Primary brain tumors are classified according to the tissue of phylogenic origin.

More information

J Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION VOLUME 27 NUMBER 8 MARCH 10 2009 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients

More information

Concepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015

Concepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015 Concepts for a personalized neurosurgical oncology Jörg-Christian Tonn Dept. of Neurosurgery Ludwig-Maximilian University München Großhadern Germany XXIV Annual Conference Pietro Paoletti 27. November

More information

Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme

Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Biopsy-Only Glioblastoma Multiforme Adam J. Kole, MD, PhD 1 ; Henry S. Park, MD, MPH 1 ; Debra N. Yeboa, MD 1 ; Charles E. Rutter, MD 1 ; Christopher

More information

CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION *

CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION * CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION * Alessandro Olivi, MD, Jaishri Blakeley, MD, and Allen K. Sills, MD, FACS ABSTRACT The management of glioma

More information

Oligodendroglial Tumors: A Review

Oligodendroglial Tumors: A Review Oligodendroglial Tumors: A Review Sajeel Chowdhary, MD H Lee Moffitt Cancer Center and Research Institute Marc C Chamberlain, MD H Lee Moffitt Cancer Center and Research Institute Corresponding author:

More information

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC randomised trial

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC randomised trial Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial M J van den Bent, D Afra, O de Witte, M Ben Hassel, S

More information

Original. Key words: Glioblastoma multiforme, temozolomide, radiation NEMROCK

Original. Key words: Glioblastoma multiforme, temozolomide, radiation NEMROCK Kasr. El-ain. J. of Clin. Oncol. nucl. med. vol.2, no.2, apr. 2006:14-20 NEMROCK Original Article Radiotherapy and Temozolomide Compared With Radiotherapy Alone in Newly Diagnosed Glioblastoma Multiforme

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Brachytherapy, Intracavitary Balloon Catheter for Brain Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: brachytherapy_intracavitary_balloon_catheter_for_brain_cancer

More information

THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa

THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.

More information

Key Words. Oligodendroglioma Oligoastrocytoma 1p 19q MGMT Temozolomide

Key Words. Oligodendroglioma Oligoastrocytoma 1p 19q MGMT Temozolomide The Oncologist The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Neuro-Oncology Oligodendrogliomas:

More information

Related Policies None

Related Policies None Medical Policy MP 2.04.113 BCBSA Ref. Policy: 2.04.113 Last Review: 05/30/2018 Effective Date: 05/30/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational

More information

Stephanie E. Combs Æ Marc Bischof Æ Thomas Welzel Æ Holger Hof Æ Susanne Oertel Æ Jürgen Debus Æ Daniela Schulz-Ertner

Stephanie E. Combs Æ Marc Bischof Æ Thomas Welzel Æ Holger Hof Æ Susanne Oertel Æ Jürgen Debus Æ Daniela Schulz-Ertner J Neurooncol (2008) 89:205 210 DOI 10.1007/s11060-008-9607-4 CLINICAL-PATIENT STUDIES Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT)

More information

Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis

Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis G. Pesce 1, A. Bordoni, F. Montanaro, R. Renella 3, A. Richetti 1, D. Boscherini 3, S. Mauri 4,

More information

Survival Analysis of Glioblastoma Multiforme

Survival Analysis of Glioblastoma Multiforme DOI:10.22034/APJCP.2018.19.9.2613 RESEARCH ARTICLE Editorial Process: Submission:04/24/2018 Acceptance:08/19/2018 Supapan Witthayanuwat, Montien Pesee*, Chunsri Supaadirek, Narudom Supakalin, Komsan Thamronganantasakul,

More information

High-Grade Gliomas. Andrew B. Lassman, Diana Matceyevsky, and Benjamin W. Corn ETIOLOGY AND EPIDEMIOLOGY PREVENTION AND EARLY DETECTION

High-Grade Gliomas. Andrew B. Lassman, Diana Matceyevsky, and Benjamin W. Corn ETIOLOGY AND EPIDEMIOLOGY PREVENTION AND EARLY DETECTION C H A P T E R 27 High-Grade Gliomas Andrew B. Lassman, Diana Matceyevsky, and Benjamin W. Corn INCIDENCE There are approximately 68,000 new cases of brain tumors diagnosed in the United States each year.

More information

4.4 CNS malignancy. Radiotherapy fractionation in the CNS

4.4 CNS malignancy. Radiotherapy fractionation in the CNS 4.4 CNS malignancy Radiotherapy fractionation in the CNS 4.4.1 Two important considerations underpin choice of treatment fractionation in neuro-oncology. Firstly, the results of treatment vary widely and,

More information

This study was designed to evaluate an online prognosis

This study was designed to evaluate an online prognosis Neuro-Oncology 15(8):1074 1078, 2013. doi:10.1093/neuonc/not033 Advance Access publication March 29, 2013 NEURO-ONCOLOGY Can the prognosis of individual patients with glioblastoma be predicted using an

More information

Neurocognitive Assessment in Patients with Brain Metastases. Martin Klein VU University Medical Center Amsterdam, The Netherlands

Neurocognitive Assessment in Patients with Brain Metastases. Martin Klein VU University Medical Center Amsterdam, The Netherlands Neurocognitive Assessment in Patients with Brain Metastases Martin Klein VU University Medical Center Amsterdam, The Netherlands Treatment Outcomes I Traditional/primary endpoints of efficacy:! Physician

More information

Glioblastoma (GBM) is the most common and

Glioblastoma (GBM) is the most common and Neuro-Oncology 12(6):595 602, 2010. doi:10.1093/neuonc/noq008 Advance Access publication February 11, 2010 NEURO-ONCOLOGY Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with

More information

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma www.jkns.or.kr http://dx.doi.org/10.3340/jkns.2013.54.6.489 J Korean Neurosurg Soc 54 : 489-495, 2013 Print ISSN 2005-3711 On-line ISSN 1598-7876 Copyright 2013 The Korean Neurosurgical Society Clinical

More information

Department of Medical Oncology, National Cancer Institute of Aviano, Aviano (PN) Italy 3

Department of Medical Oncology, National Cancer Institute of Aviano, Aviano (PN) Italy 3 WCRJ 2014; 1 (4): e401 RADIOCHEMOTHERAPY FOR UNRESECTABLE GLIOBLASTOMA MULTIFORME: A MONO- INSTITUTIONAL EXPERIENCE M. COLELLA 1, F. FIORICA 1, P. API 1, A. STEFANELLI 1, B. URBINI 2, A. SGUALDO 1, D.

More information

LOW GRADE ASTROCYTOMAS

LOW GRADE ASTROCYTOMAS LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous

More information

Defining pseudoprogression in glioblastoma multiforme

Defining pseudoprogression in glioblastoma multiforme European Journal of Neurology 2013, 20: 1335 1341 CME ARTICLE doi:10.1111/ene.12192 Defining pseudoprogression in glioblastoma multiforme E. Van Mieghem a, A. Wozniak b, Y. Geussens c, J. Menten c, S.

More information

Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community

Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community The Harvard community has made this article openly available. Please

More information

NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99

NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99 Brain tumours (primary) and brain metastases in adults NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES

MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN

More information

Bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly-diagnosed glioblastoma

Bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly-diagnosed glioblastoma Bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly-diagnosed glioblastoma Design and analysis of single-arm Phase II clinical trial

More information

NCCP Chemotherapy Regimen. Temozolomide with Radiotherapy (RT) and Adjuvant Therapy

NCCP Chemotherapy Regimen. Temozolomide with Radiotherapy (RT) and Adjuvant Therapy Temozolomide with Radiotherapy (RT) INDICATIONS FOR USE: Regimen Code ISMO Contributor: Prof Maccon Keane Page 1 of 6 *Reimbursement Status INDICATION ICD10 Adult patients with newly-diagnosed glioblastoma

More information

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2013 Prognostic or predictive value of MGMT promoter methylation in gliomas

More information

The Response to Chemo Radiation. Therapy in Unresectable Glioblastoma

The Response to Chemo Radiation. Therapy in Unresectable Glioblastoma Research Article imedpub Journals http://www.imedpub.com Journal of Clinical Epigenetics DOI: 10.21767/2472-1158.100054 Abstract The Response to Chemo Radiation Therapy in Unresectable Glioblastoma Multiforme

More information

Survival Following CyberKnife Radiosurgery and Hypofractionated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme

Survival Following CyberKnife Radiosurgery and Hypofractionated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme Technology in Cancer Research and Treatment ISSN 1533-0346 Volume 7, Number 3, June 2008 Adenine Press (2008) Survival Following CyberKnife Radiosurgery and Hypofractionated Radiotherapy for Newly Diagnosed

More information

Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma

Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma 463 Original Article Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma The Singapore Cancer Network (SCAN) Neuro-Oncology Workgroup Abstract Introduction: The SCAN Neuro-Oncology

More information